| Published work on thymosin beta-4, the parent protein of TB-500PubMed listing | Animal | Multiple rodent injury models | — | Placeholder seed record. This literature concerns thymosin beta-4, the full parent protein — not the fragment sold as TB-500. Vendors frequently cite this body of work when listing TB-500; the two are not the same molecule, and evidence about one is not evidence about the other. | Listing |
|---|
| Early-phase human work on thymosin beta-4PubMed listing | Human — controlled trial | Not recorded | — | Placeholder seed record. A small number of early-phase human studies of the parent protein exist in the listed literature. None were carried through to marketing approval in any jurisdiction, and none concern the TB-500 fragment as sold. | Listing |
|---|
| Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysisArchives of pathology & laboratory medicine · 1993 | Case report | Not recorded | — | Patients with malignant thymoma rarely may also have a peripheral T-cell lymphocytosis. "Lymphocyte spillover" from the thymus into the peripheral blood as well as a second, associated neoplasm (ie, T-cell chronic lymphocytic leukemia) are two hypotheses that have been proposed to explain this clinical phenomenon. We describe another patient with a lymphocyte-rich malignant thymoma associated with peripheral T-cell lymphocytosis. At the time of initial diagnosis, the patient'… | PMID 8382915 |
|---|
| Thymosins: structure, function and therapeutic applicationsThymus · 1984 | Human — controlled trial | Not recorded | — | Using a partially purified preparation, thymosin fraction 5, we have documented that thymosin can correct many of the immunological deficiencies resulting from the lack of thymosin function in animal models and in humans. Ongoing studies indicate that there is a family of biologically active peptides within fraction 5 that act on T-cell subpopulations to maintain normal immunological reactivity. Several of these peptides have been purified to homogeneity. Two peptides, thymos… | PMID 6087503 |
|---|
| A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteersAnnals of the New York Academy of Sciences · 2010 | Human — controlled trial | Not recorded | — | Synthetic thymosin beta 4 (Tbeta4) may have a potential use in promoting myocardial cell survival during acute myocardial infarction. Four cohorts, with 10 healthy subjects each, were given a single intravenous dose of placebo or synthetic Tbeta4. Cohorts received ascending doses of either 42, 140, 420, or 1260 mg. Following safety review, subjects were given the same dose regimen daily for 14 days. Safety evaluations, incidence of Treatment-Emergent Adverse Events, and pharm… | PMID 20536472 |
|---|
| The effect of thymosin treatment of venous ulcersAnnals of the New York Academy of Sciences · 2010 | Human — controlled trial | Not recorded | — | Venous ulcers are responsible for about 70% of the chronic ulcers of the lower limbs. Standard of care includes compression, dressings, debridement of devitalized tissue, and infection control. Thymosin beta 4 (Tbeta4), a synthetic copy of the naturally occurring 43 amino-acid peptide, has been found to have wound healing and anti-inflammatory properties, and is thought to exert its therapeutic effect through promotion of keratinocyte and endothelial cell migration, increased… | PMID 20536470 |
|---|